Table 2.
Participant serological status at enrollment and over the study period.
| All Participants (n=200) | |
|---|---|
| At Enrollment | |
| Vaccinated, n (%) | 131 (65.5%) |
| Moderna (mRNA-1273), n (%) | 20 (15.2%) |
| Pfizer (BNT162b2), n (%) | 110 (84.0%) |
| J&J/Janssen (JNJ-78436735), n (%) | 1 (0.8%) |
| Not Vaccinated, n (%) | 69 (34.5%) |
| Prior Infection, n (%) | 53 (26.5%) |
| No Prior Infection, n (%) | 147 (73.5%) |
| Prior Vaccination and Infection, n (%) | 25 (12.5%) |
| Prior Vaccination without Infection, n (%) | 106 (53.0%) |
| No Vaccination with Infection, n (%) | 28 (14.0%) |
| No Vaccination without Infection, n (%) | 41 (20.5%) |
| Vaccination Over the Study Period | |
| Unvaccinated to Vaccinated, n (%) | 35/69 (50.7%) |
| Moderna (mRNA-1273), n (%) | 3 (8.6%) |
| Pfizer (BNT162b2), n (%) | 30 (85.7%) |
| J&J/Janssen (JNJ-78436735), n (%) | 2 (5.7%) |
| Received Booster Vaccination, n (%) | 67/166 (40.4%) |
| At Study Completion | |
| Vaccinated, n (%) | 166/200 (83.0%) |
| Moderna (mRNA-1273), n (%) | 23 (13.9%) |
| Pfizer (BNT162b2), n (%) | 140 (84.3%) |
| J&J/Janssen (JNJ-78436735), n (%) | 3 (1.8%) |
| Not Vaccinated, n (%) | 29/200 (14.5%) |
| Unknown, n (%) | 5/200 (2.5%) |
| Prior Infection, n (%) | 70/200 (35.0%) |
| No Prior Infection, n (%) | 120/200 (60.00%) |
| Unknown, n (%) | 10/200 (5.0%) |
Data are represented as the number of participants (n) and the percentage of participants in the cohort or group (%), unless otherwise stated. The number of participants who were vaccinated and infected at study completion is representative of each participant while they were in the study.